Analogs in the treatment of chronic hepatitis B: real life experience with tenofovir and entecavir

Rosanna Villani, Roberta Forlano, Gianluigi Vendemiale, Gaetano Serviddio

DOI: https://doi.org/10.7175/cmi.v9i2.1192

Abstract

INTRODUCTION: Tenofovir and entecavir are potent antiviral agents. By suppressing viral replication, they induce histological improvement and finally delay the progression of chronic hepatitis B and the development of complications. They are rarely associated with serious side effects. Our data from a real life experience support data from the literature and suggest some minimal difference that may be useful in tailoring therapy.

PATIENTS AND METHODS: We retrospectively analyzed 54 patients affected by chronic hepatitis B (31 and 23 treated by entecavir and tenofovir, respectively). Eight patients were cirrhotic. At baseline and 4-12 and 24 weeks after starting therapy, biochemical and virological analysis were performed in all patients. Renal function tests (serum creatinine, creatinine clearance and blood urea), serum (calcium and phosphate blood level) and urine electrolyte were also studied.

RESULTS: All the patients reached virological control within 24 weeks. Only in the group treated by tenofovir we observed a complete viral suppression within 12 weeks. Some patients treated with tenofovir showed increased creatinine clearance without serum creatinine alteration. No significant side effects were reported with the exception of one case of persistent headache in the entecavir group for which the drug was suspended.

CONCLUSIONS: Entecavir and tenofovir are effective in suppressing viral replication in patients with chronic hepatitis B. Tenofovir is more potent than entecavir and viral replication is blocked within 12 weeks of therapy. Tenofovir administration is associated with slight increase of creatinine clearance without alteration of serum creatinine levels. The choice of one or the other should be made according to target and specific patients characteristics. In patients with high serum viral load where the complete and quick control of viral replication is the main target, tenofovir may represent the best choice.

Keywords

Tenofovir; Entecavir; Chronic Hepatitis B; Retrospective study

Full Text

HTML PDF

References

  • Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92; http://dx.doi.org/10.1016/S0140-6736(09)60207-5
  • El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76; http://dx.doi.org/10.1053/j.gastro.2007.04.061
  • Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 353: 1253-7; http://dx.doi.org/10.1016/S0140-6736(98)09148-X
  • Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73; http://dx.doi.org/10.1001/jama.295.1.65
  • Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-56; http://dx.doi.org/10.1016/j.jhep.2010.02.035
  • Triolo M, Della CC, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int 2014; 34 Suppl 1: 139-45; http://dx.doi.org/10.1111/liv.12394
  • Calvaruso V, Craxi A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int 2014; 34 Suppl 1: 85-90; http://dx.doi.org/10.1111/liv.12395
  • Fung J, Lai CL, Seto WK, et al. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 2011; 66: 2715-25; http://dx.doi.org/10.1093/jac/dkr388
  • Lee CI, Kwon SY, Kim JH, et al. Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. Gut Liver 2014; 8: 64-9; http://dx.doi.org/10.5009/gnl.2014.8.1.64
  • Miquel M, Nunez O, Trapero-Marugan M, et al. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann Hepatol 2013; 12: 205-12
  • Zuo SR, Zuo XC, Wang CJ, et al. A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection. J Clin Pharmacol 2014 Oct 7 [Epub ahead of print]; http://dx.doi.org/10.1002/jcph.409
  • Società Italiana di Patologia Clinica e Medicina di Laboratorio. www.sipmel.it (ultimo accesso giugno 2015)
  • Ke W, Liu L, Zhang C, et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One 2014; 9: e98865; http://dx.doi.org/10.1371/journal.pone.0098865
  • Srivastava M, Rungta S, Dixit VK, et al. Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective. Antiviral Res 2013; 100: 300-5; http://dx.doi.org/10.1016/j.antiviral.2013.08.020

Statistics

Abstract: 858 views
HTML: 776 views
PDF: 220 views

Refbacks

  • There are currently no refbacks.




© SEEd srl